=> d l21
L21 HAS NO ANSWERS
L21 STR



REP G1=(0-5) CH2
REP G2=(1-7) CH2
VAR G3=3/2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 1
NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE

=> d l11
L11 HAS NO ANSWERS
L11 SCR 1840

=> d hit l25

L25 ANSWER 1 OF 47 REGISTRY COPYRIGHT 2002 ACS

=> d his l25

(FILE 'REGISTRY' ENTERED AT 12:11:41 ON 25 JUL 2002)
L25 47 S L21 AND L11 FUL

L5 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2002 ACS
RN **200006-35-5** REGISTRY
CN **L-Proline, 1-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI)** (CA INDEX NAME)
FS STEREOSEARCH
MF C22 H25 N O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L5 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2002 ACS
RN **200006-27-5** REGISTRY
CN **L-Proline, 1-[2-(diphenylmethoxy)ethyl]-, methyl ester (9CI)** (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H25 N O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L5 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2002 ACS
RN **2133-40-6** REGISTRY
CN **L-Proline, methyl ester, hydrochloride (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Proline, methyl ester, hydrochloride, L- (6CI, 7CI, 8CI)**
OTHER NAMES:
CN **(S)-Proline methyl ester hydrochloride**
CN **Methyl L-prolinate hydrochloride**
CN **Methyl prolinate hydrochloride**
CN **Methyl proline hydrochloride**

FS STEREOSEARCH
DR 190017-88-0
MF C6 H11 N O2 . Cl H
CI COM
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, GMELIN*, IFICDB, IFIPAT, IFIUDB, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (2577-48-2)

Absolute stereochemistry. Rotation (-).



● HCl

588 REFERENCES IN FILE CA (1967 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
589 REFERENCES IN FILE CAPLUS (1967 TO DATE)
5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

AN 1985:442656 CAPLUS
DN 103:42656
TI N-Substituted pyrrolidineacetic acids and their esters
IN Bondinell, William E.; Lafferty, John J.; Zirkle, Charles L.
PA Smithkline Beckman Corp., USA
SO U.S., 7 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4514414	A	19850430	US 1982-436232	19821025

OS CASREACT 103:42656
GI



I



II



III

AB Pharmaceutical compns. useful as inhibitors of GABA [56-12-2] uptake comprise the title compds. I [R = cyclohexyl, thienyl, or (un)substituted Ph; R1 and R2 = H, Cl, F, Me, or MeO; R3 = H or Me; R4 = H or C1-3 alkyl; n = 2 or 3], II (R1, R2, R3, and R4 an n as above), and III (R1 and R4 as above) and their optical isomers. I were prepd. by the reaction of an alkenyl halide with an ester of an N-substituted pyrrolidineacetic acid (IV), II were prepd. by the reaction of IV with a diphenylalkyl group, and III were prepd. by the reaction of IV with an ester of an appropriately substituted phenylalkyne. Thus, a capsule formulation contained 1-(4,4-diphenyl-3-butenyl)-3-pyrrolidineacetic acid (I; R = Ph, R1-R4 = H) [89203-55-4] 50, Mg stearate 2, and lactose 200 mg/capsule.

IT **97182-43-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and hydrolysis of)

RN 97182-43-9 CAPLUS
CN 3-Pyrrolidineacetic acid, 1-[4-(3-chlorophenyl)-4-phenyl-3-butenyl]-, methyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


Ph
Z
N
Cl
O
OMe

(11b) STN

Connecting via Winsock to STN

Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:ssspta1626gms
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Dec 17	The CA Lexicon available in the CAPLUS and CA files
NEWS 3	Feb 06	Engineering Information Encompass files have new names
NEWS 4	Feb 16	TOXLINE no longer being updated
NEWS 5	Apr 23	Search Derwent WPINDEX by chemical structure
NEWS 6	Apr 23	PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS 7	May 07	DGENE Reload
NEWS 8	Jun 20	Published patent applications (A1) are now in USPATFULL
NEWS 9	JUL 13	New SDI alert frequency now available in Derwent's DWPI and DPCI
NEWS 10	Aug 23	In-process records and more frequent updates now in MEDLINE
NEWS 11	Aug 23	PAGE IMAGES FOR 1947-1966 RECORDS IN CAPLUS AND CA
NEWS 12	Aug 23	Adis Newsletters (ADISNEWS) now available on STN
NEWS 13	Sep 17	IMSworld Pharmaceutical Company Directory name change to PHARMASEARCH
NEWS 14	Oct 09	Korean abstracts now included in Derwent World Patents Index
NEWS 15	Oct 09	Number of Derwent World Patents Index updates increased
NEWS 16	Oct 15	Calculated properties now in the REGISTRY/ZREGISTRY File
NEWS 17	Oct 22	Over 1 million reactions added to CASREACT
NEWS 18	Oct 22	DGENE GETSIM has been improved
NEWS 19	Oct 29	AAASD no longer available
NEWS 20	Nov 19	New Search Capabilities USPATFULL and USPAT2
NEWS 21	Nov 19	TOXCENTER(SM) - new toxicology file now available on STN
NEWS 22	Nov 29	COPPERLIT now available on STN
NEWS 23	Nov 29	DWPI revisions to NTIS and US Provisional Numbers
NEWS 24	Nov 30	Files VETU and VETB to have open access

NEWS EXPRESS	August 15 CURRENT WINDOWS VERSION IS V6.0c, CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP), AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

Golam Shameem

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:08:50 ON 02 DEC 2001

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'REGISTRY' ENTERED AT 13:09:06 ON 02 DEC 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 30 NOV 2001 HIGHEST RN 372937-30-9
DICTIONARY FILE UPDATES: 30 NOV 2001 HIGHEST RN 372937-30-9

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 09763617.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



example 16(b)
Page 30

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 13:09:38 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      5 TO ITERATE

100.0% PROCESSED       5 ITERATIONS                              1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            5 TO      234
PROJECTED ANSWERS:               1 TO       80

L2            1 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 13:09:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     38 TO ITERATE

100.0% PROCESSED      38 ITERATIONS                              3 ANSWERS
SEARCH TIME: 00.00.01

L3            3 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             133.56     133.71

FILE 'CAPLUS' ENTERED AT 13:09:56 ON 02 DEC 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)
```

Golam Shameem

FILE COVERS 1947 - 2 Dec 2001 VOL 135 ISS 24
FILE LAST UPDATED: 30 Nov 2001 (20011130/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.


```
=> d his

     (FILE 'HOME' ENTERED AT 13:08:50 ON 02 DEC 2001)

     FILE 'REGISTRY' ENTERED AT 13:09:06 ON 02 DEC 2001
L1                STRUCTURE UPLOADED
L2              1 S L1
L3              3 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 13:09:56 ON 02 DEC 2001

=> s l3
L4              3 L3

=> d l4 ibib abs hit str
'STR' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
```

Golam Shameem

IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers; SCAN must be entered on the same line as the DISPLAY, e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, IPC, and NCL

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT) containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):end

=> d l4 ibib abs hitstr tot

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2001:132748 CAPLUS
DOCUMENT NUMBER: 134:178816
TITLE: Preparation of amino acid derivatives as pharmaceuticals for treatment of neurological and neuropsychiatric disorders
INVENTOR(S): Ognyanov, Vassil Iliya; Borden, Laurence A.; Bell, Stanley Charles; Zhang, Jing
PATENT ASSIGNEE(S): Allelix Neuroscience Inc., USA
SOURCE: U.S., 52 pp., Cont.-in-part of U. S. Ser. No.656,063,

Golam Shameem

abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6191165	B1	20010220	US 1997-866007	19970530
US 20010012857	A1	20010809	US 2001-757011	20010109

PRIORITY APPLN. INFO.:

US 1996-41503	P	19960531
US 1996-41504	P	19960531
US 1996-655912	B2	19960531
US 1996-656063	B2	19960531
US 1997-44387	P	19970227
US 1997-70900	P	19970227
US 1997-808754	B2	19970227
US 1997-808755	A2	19970227
US 1997-807682	A2	19970228
US 1997-866007	A3	19970530

OTHER SOURCE(S): MARPAT 134:178816

AB Amino acid derivs. R2RxRyXR1NR3(R3*)nCR4R4*R5 [X = N, C (R2 not present when X = N); R2 = H, alkyl, alkoxy, cyano, alkanoyl, etc.; Rx, Ry = aryl, heteroaryl, adamantyl, or nonarom. ring linked to X via a single bond, alkylene, etc.; R1 = alkylene, iminooxyethylene, etc.; R3 = H, alkyl, (un)substituted Ph or phenylalkyl, etc.; R3* = alkyl, O; n = 0, 1; R4, R4* = H, alkyl, hydroxyalkyl; R5 = (un)substituted carbamoyl, carboxy, aminosulfonyl, phosphoryl, etc.] were prepd. as pharmaceuticals for treatment of neurol. and neuropsychiatric disorders. Thus, N-(4,4-diphenyl-3-butenyl)glycine Et ester was by alkylation of glycine Et ester hydrochloride with 4-bromo-1,1-diphenyl-1-butene. Binding assays to measure interaction of compds. with the glycine site on the NMDA receptor are illustrated.

IT **200006-35-5P 200006-37-7P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amino acid derivs. as pharmaceuticals for treatment of neurol. and neuropsychiatric disorders)

RN 200006-35-5 CAPLUS
CN L-Proline, 1-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 200006-37-7 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-2-carboxylic acid, 3-(4,4-diphenyl-3-butenyl)-, methyl ester, (1R,2R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Golam Shameem



REFERENCE COUNT: 29
REFERENCE(S):
(1) Ali, F; J Med Chem 1985, V28, P653 CAPLUS
(2) Anon; DE 3010599 1980 CAPLUS
(3) Anon; BE 885303 1981 CAPLUS
(5) Anon; EP 0068544 A2 1983 CAPLUS
(6) Anon; EP 0221572 A2 1987 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:157915 CAPLUS
DOCUMENT NUMBER: 132:194656
TITLE: Preparation of proline derivatives and related compounds as GABA uptake inhibitors
INVENTOR(S): Wanner, Klaus; Fuelep, Guenther; Hoefner, Georg
PATENT ASSIGNEE(S): Germany
SOURCE: Ger. Offen., 36 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19840611	A1	20000309	DE 1998-19840611	19980905
WO 2000014064	A2	20000316	WO 1999-EP6486	19990903
WO 2000014064	A3	20000720		
W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RU, TR, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9959726	A1	20000327	AU 1999-59726	19990903
EP 1109783	A2	20010627	EP 1999-968664	19990903
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: DE 1998-19840611 A 19980905
WO 1999-EP6486 W 19990903
OTHER SOURCE(S): MARPAT 132:194656
GI



I

Golam Shameem

AB Title compds. [I; R1-R7 = H, OH, halo, cyano, alkyl, alkenyl, alkynyl, (substituted) aryl, heteroaryl, etc.; R1R2 and/or R3R4 and/or R5R6 = (substituted) alkylidene, O; pairs of adjoining R1-R7 = double bond; X = CO2M, group physiol. convertible to CO2M; M = H, pharmaceutically acceptable cation; Z = Y3CO, Y2C:CR15, Y2C:NO; R15 = H, alkyl, halo; Y = (substituted) aryl, heteroaryl; A1 = (CR8R9)n, (substituted) alkylene, or a combination thereof; n .gtoreq.2; R8, R9 = H, alkyl, halo, OH, etc.; A2 = (CR10R11)m; R10, R11 = H, alkyl, halo; m .gtoreq.2], were prepd. as GABA uptake inhibitors (no data). Thus, L-proline Me ester hydrochloride (prepn. given), KI, K2CO3, and 4,4-diphenylbut-3-en-1-yl bromide were stirred 46 h in acetone to give 52.4% Me (S)-N-(4,4-diphenylbut-3-en-1-yl)pyrrolidine-2-carboxylate.

IT **200006-35-5P 259868-39-8P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of proline derivs. and related compds. as GABA uptake inhibitors)

RN 200006-35-5 CAPLUS
CN L-Proline, 1-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 259868-39-8 CAPLUS
CN D-Proline, 1-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 8
REFERENCE(S):
(2) Anon; EP 0231996 A2 CAPLUS
(3) Anon; EP 0236342 B1 CAPLUS
(4) Anon; EP 0374801 A2 CAPLUS
(5) Anon; US 4514414 CAPLUS
(6) Anon; US 4610995 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1997:803807 CAPLUS
DOCUMENT NUMBER: 128:48490

Golam Shameem

TITLE: Preparation of amino acid derivatives as pharmaceuticals for treatment of neurological and neuropsychiatric disorders

INVENTOR(S): Ognyanov, Vassil Iliya; Borden, Laurence; Bell, Stanley Charles; Zhang, Jing

PATENT ASSIGNEE(S): Trophix Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9745115	A1	19971204	WO 1997-US9450	19970529
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2254833	AA	19971204	CA 1997-2254833	19970529
AU 9731530	A1	19980105	AU 1997-31530	19970529
AU 730789	B2	20010315		
EP 1014966	A1	20000705	EP 1997-926871	19970529
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9709501	A	20001107	BR 1997-9501	19970529
NO 9805711	A	19981207	NO 1998-5711	19981207

PRIORITY APPLN. INFO.:

US 1996-655912	A	19960531
US 1996-656063	A	19960531
US 1997-808754	A	19970227
US 1997-808755	A	19970227
US 1997-807682	A	19970227
WO 1997-US9450	W	19970529

OTHER SOURCE(S): MARPAT 128:48490

AB Amino acid derivs. R2RxRyXR1NR3(R3*)nCR4R4*R5 [X = N, C (R2 not present when X = N); R2 = H, alkyl, alkoxy, cyano, alkanoyl, etc.; Rx, Ry = aryl, heteroaryl, adamantyl, or nonarom. ring linked to X via a single bond, alkylene, etc.; R1 = alkylene, iminooxyethylene, etc.; R3 = H, alkyl, (un)substituted Ph or phenylalkyl, etc.; R3* = alkyl, O; n = 0, 1; R4, R4* = H, alkyl, hydroxyalkyl; R5 = (un)substituted carbamoyl, carboxy, aminosulfonyl, phosphoryl, etc.] were prepd. as pharmaceuticals for treatment of neurol. and neuropsychiatric disorders. Thus, N-(4,4-diphenyl-3-butenyl)glycine Et ester was by alkylation of glycine Et ester hydrochloride with 4-bromo-1,1-diphenyl-1-butene. Binding assays to measure interaction of compds. with the glycine site on the NMDA receptor are illustrated.

IT **200006-35-5P 200006-37-7P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amino acid derivs. as pharmaceuticals for treatment of neurol. and neuropsychiatric disorders)

RN 200006-35-5 CAPLUS

CN L-Proline, 1-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI) (CA INDEX NAME)

Golam Shameem

Absolute stereochemistry.



RN 200006-37-7 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-2-carboxylic acid, 3-(4,4-diphenyl-3-butenyl)-, methyl ester, (1R,2R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	13.55	147.26

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.76	-1.76

STN INTERNATIONAL LOGOFF AT 13:11:33 ON 02 DEC 2001

Connection closed by remote host

```
=> s l25
L26         11 L25

=> s l26 and l20
L27          1 L26 AND L20

=> d bib

L27  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2002 ACS
AN   2000:157915  CAPLUS
DN   132:194656
TI   Preparation of proline derivatives and related compounds as GABA uptake
     inhibitors
IN   Wanner, Klaus; Fuelep, Guenther; Hoefner, Georg
PA   Germany
SO   Ger. Offen., 36 pp.
     CODEN: GWXXBX
DT   Patent
LA   German
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   DE 19840611        A1   20000309       DE 1998-19840611 19980905
     WO 2000014064      A2   20000316       WO 1999-EP6486   19990903
     WO 2000014064      A3   20000720
         W:  AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RU, TR, US, ZA
         RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE
     AU 9959726         A1   20000327       AU 1999-59726    19990903
     EP 1109783         A2   20010627       EP 1999-968664   19990903
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI
PRAI DE 1998-19840611  A    19980905
     WO 1999-EP6486    W    19990903
OS   MARPAT 132:194656
RE.CNT  8     THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> s l26 not l27
L28         10 L26 NOT L27

=> d bib abs hitstr 10

L28  ANSWER 10 OF 10  CAPLUS  COPYRIGHT 2002 ACS
AN   1984:114852  CAPLUS
DN   100:114852
TI   Novel inhibitors of .gamma.-aminobutyric acid (GABA) uptake:
     Anticonvulsant actions in rats and mice
AU   Yunger, Libby M.; Fowler, Philip J.; Zarevics, Peter; Setler, Paulette E.
CS   Dep. Pharmacol., Smith Kline and French Lab., Philadelphia, PA, USA
SO   J. Pharmacol. Exp. Ther. (1984), 228(1), 109-15
     CODEN: JPETAB; ISSN: 0022-3565
DT   Journal
LA   English
AB   SKF 89976A [N-(4,4-diphenyl-3-butenyl)-nipecotic acid]  [85375-85-5] and
     SKF 100330A [N-(4,4-diphenyl-3-butenyl)-guvacine)  [85375-88-8] represent
     a series of potent, orally active inhibitors of GABA  [56-12-2] uptake.
     These compds. were also potent anticonvulsants when administered either
     orally or i.p. to rats.  Both compds. attenuated the forelimb extensor
     component of bicuculline-induced convulsions, but had no effect on
     strychnine-induced convulsions, indicating that they were acting through a
```

GABAergic mechanism in vivo. Two animals models known to indicate anticonvulsant efficacy in man are inhibition of maximal electroshock seizures (MES) and inhibition of pentylenetetrazol (PTZ) convulsions in either rats or mice. SKF 89976A, SKF 100330A and several related compds. were potent inhibitors of PTZ convulsions in rats. SKF 100330A also inhibited MES convulsions in rats. In contrast, neither compd. inhibited MES or electroshock seizure threshold in mice, and whereas both compds. inhibited the tonic phase of PTZ convulsions in approx. 50% of the mice tested, this inhibition was not dose-related. Thus, the rat appears to be a more suitable species for further testing of these compds. The family of compds. represented by SKF 89976A and SKF 100330A may thus have clin. relevant anticonvulsant activity.

IT **89203-55-4**
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(anticonvulsant activity of and GABA uptake inhibition by)

RN 89203-55-4 CAPLUS

CN 3-Pyrrolidineacetic acid, 1-(4,4-diphenyl-3-butenyl)- (9CI) (CA INDEX NAME)



=> d bib abs 1-9

L28 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2002 ACS
AN 2000:493419 CAPLUS
DN 133:109984
TI Compositions for treating frequent urination and urinary incontinence
IN Hashimoto, Tadatoshi; Kamo, Izumi
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000041728	A1	20000720	WO 2000-JP74	20000111
	W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	JP 2000264848	A2	20000926	JP 2000-6127	20000111
	EP 1142584	A1	20011010	EP 2000-900169	20000111
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	JP 1999-5556	A	19990112		
	WO 2000-JP74	W	20000111		

AB A GABA uptake inhibitor is useful in prepg. compns. for treating frequent

urination and urinary incontinence. Capsules were formulated contg. NO-711-HCl 25, lactose 55, talc 16 and magnesium stearate 4 mg.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2002 ACS
AN 1997:772607 CAPLUS
DN 128:43856
TI Use of GABA uptake inhibitors as antitussive agents
IN Bondinell, William E.; Underwood, David C.; Kotzer, Charles J.
PA Smithkline Beecham Corporation, USA; Bondinell, William E.; Underwood, David C.; Kotzer, Charles J.
SO PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9743902	A1	19971127	WO 1997-US8948	19970523
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 912091	A1	19990506	EP 1997-928667	19970523
	R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
	JP 2000511538	T2	20000905	JP 1997-542846	19970523
	US 6121290	A	20000919	US 1998-194325	19981124
PRAI	US 1996-18258P	P	19960524		
	WO 1997-US8948	W	19970523		

AB A method is provided for treating cough in a mammal, including a human, which comprises administering an effective amt. of an inhibitor of GABA uptake.

L28 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2002 ACS
AN 1991:484814 CAPLUS
DN 115:84814
TI GABA-uptake inhibitors: construction of a general pharmacophore model and successful prediction of a new representative
AU N'Goka, Victor; Schlewer, Gilbert; Linget, Jean Michel; Chambon, Jean Pierre; Wermuth, Camille Georges
CS Cent. Neurochim., CNRS, Strasbourg, 67084, Fr.
SO J. Med. Chem. (1991), 34(8), 2547-57
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
GI



I

AB A model for the pharmacophore of GABA-uptake inhibitors was established using published structure-activity data and mol. modeling. The model accounted for the activities of different classes of GABA-uptake inhibitors. Analogs of guvacine and nipecotic acid substituted at position 6 were synthesized in order to confirm the model. 6-(3,3-Diphenylpropyl)guvacine (I), which fit well with the pharmacophore,

had an in vitro IC50 of 0.1 .mu.M. This value is as good as those of the best GABA-uptake inhibitors known today.

L28 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2002 ACS
AN 1990:509794 CAPLUS
DN 113:109794
TI .gamma.-Aminobutyric acid inhibition of histamine-induced inositol phosphate formation in guinea pig cerebellum: comparison with guinea pig and rat cerebral cortex
AU Crawford, Melissa L. A.; Carswell, Heather; Young, J. M.
CS Dep. Pharmacol., Univ. Cambridge, Cambridge, CB2 1QJ, UK
SO Br. J. Pharmacol. (1990), 100(4), 867-73
CODEN: BJPCBM; ISSN: 0007-1188
DT Journal
LA English
AB .gamma.-Aminobutyric acid (GABA), 2 mM, inhibited basal accumulation of [3H]inositol monophosphate ([3H]-IP1) in lithium-treated slices of guinea pig cerebellum preincubated with [3H]inositol. In contrast, 2 mM GABA stimulated the accumulation of [3H]-IP1 in rat cerebral cortical slices over a 60 min incubation period, but had no significant effect in slices of guinea pig cerebral cortex. The estd. IC50 for the inhibitory action of GABA in guinea pig cerebellar slices was 0.52. GABA inhibited histamine-induced [3H]-IP1 accumulation in guinea pig cerebellar slices in a noncompetitive manner. The best-fit value for the max. level of inhibition was 74%. The estd. IC50 for GABA was 0.77 mM and was not significantly different from the IC50 for inhibition of the basal accumulation of [3H]-IP1. The response to histamine in guinea pig and rat cerebral cortical slices was also inhibited by 2 mM GABA. In guinea pig cerebellar slices 2 mM GABA potentiated histamine-induced [3H]inositol bisphosphate ([3H]-IP2) accumulation, whereas in both guinea pig and rat cerebral cortex the effect was inhibition. Isoguvacine and muscimol, GABAA-selective agonists, and (-)-baclofen, GABAB-selective agonist, had no significant effect on basal or histamine-stimulated accumulation of [3H]-IPs in guinea pig cerebellar slices. (-)-Baclofen had only a weak inhibitory effect on [3H]-IP1 accumulation in guinea pig cerebral cortex (16% inhibition with 10 .mu.M (-)-baclofen), whereas in rat cerebral cortex (-)-baclofen mimicked the inhibitory effect of GABA. Nipecotic acid (1 mM) had qual. similar effects to those of 2 mM GABA in guinea pig cerebellar slices. The competitive GABA uptake inhibitors SKF 89976A, SKF 100330A, and SKF 100561A were potent histamine H1-receptor antagonists, as indicated by the inhibition of [3H]mepyramine binding to homogenates of guinea pig cerebellum and cerebral cortex. GABA (2 mM) caused a small inhibition (12%) of [3H]inositol incorporation into total inositol phospholipids in guinea pig cerebellar slices, as in rat cerebral cortical slices, whereas 0.2 mM histamine caused a small stimulation (15%). In the presence of both GABA and histamine, [3H]inositol incorporation was unchanged from basal (101%). GABA also inhibited [3H]-IP1 formation induced by endothelin-1 in guinea pig cerebellar slices and increased, but not significantly, the amt. of [3H]-IP2 accumulated. This, taken with the inhibitory effect on basal and histamine-stimulated accumulation, suggests that the action of GABA in guinea pig cerebellar slices may be non-selective and may not be exerted through a specific GABA receptor.

L28 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2002 ACS
AN 1990:152254 CAPLUS
DN 112:152254
TI (R)-N-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]nipecotic acid binds with high affinity to the brain .gamma.-aminobutyric acid uptake carrier
AU Braestrup, Claus; Nielsen, Erik B.; Sonnewald, Ursula; Knutsen, Lars J. S.; Andersen, Knud Erik; Jansen, Jens Aas; Frederiksen, Kristen; Andersen, Peter H.; Mortensen, Alicja; Suzdak, Peter D.
CS Novo Ind. A/S, Bagsvaerd, 2880, Den.
SO J. Neurochem. (1990), 54(2), 639-47

CODEN: JONRA9; ISSN: 0022-3042
DT Journal
LA English
GI



I

AB NO 328 (I) is a potent inhibitor of [3H]GABA uptake in a rat forebrain synaptosomal prepn. (IC50 = 67 nM) and in primary cultures of neurons and astrocytes. Inhibition of [3H]GABA uptake by NO 328 is apparently of a mixed type when NO 328 is preincubated before [3H]GABA uptake; the inhibition is apparently competitive without preincubation. NO 328 itself is not a substrate for the GABA uptake carrier, but NO 328 is a selective inhibitor of [3H]GABA uptake. Binding to benzodiazepine receptors, histamine H1 receptors, and 5-hydroxytryptamine1A receptors was inhibited by NO 328 at 5-30 .mu.M, whereas several other receptors and uptake sites were unaffected. [3H]NO 328 showed saturable and reversible binding to rat brain membranes in the presence of NaCl. The specific binding of [3H]NO 328 was inhibited by known inhibitors of [3H]GABA uptake; GABA and the cyclic amino acid GABA uptake inhibitors were, however, less potent than expected. This indicates that the binding site is not identical to, but rather overlapping with, the GABA recognition site of the uptake carrier. The affinity const. for binding of [3H]NO 328 is 18 nM, and the Bmax is 669 pmol/g of original rat forebrain tissue. The regional distribution of NaCl-dependent [3H]NO 328 binding followed that of synaptosomal [3H]GABA uptake. Thus, NO 328 is a potent and selective inhibitor of neuronal and glial GABA uptake and [3H]NO 328 is a useful radioligand for labeling the GABA uptake carrier in brain membranes. In the mouse brain in vivo, [3H]NO 328 likewise showed saturable and reversible binding that could be displaced by analogs of NO 328. Further studies are needed to demonstrate whether the uptake carrier is indeed labeled by [3H]NO 328 in vivo.

L28 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2002 ACS
AN 1987:433803 CAPLUS
DN 107:33803
TI A carrier for GABA uptake exists on noradrenaline nerve endings in selective rat brain areas but not on serotonin terminals
AU Bonanno, G.; Raiteri, M.
CS Ist. Farmacol. Farmacogn., Univ. Genova, Genoa, I-16148, Italy
SO J. Neural Transm. (1987), 69(1-2), 59-70
CODEN: JNTMAH; ISSN: 0300-9564
DT Journal
LA English
AB GABA (3-300 .mu.M) increased, in a concn.-dependent manner, the basal release of tritium from rat cerebral cortex and hippocampus synaptosomes prelabeled with [3H]noradrenaline ([3H]NA); however, GABA was ineffective on hypothalamic nerve endings. The effect displayed by low concns. (<10 .mu.M) of GABA was largely bicuculline-sensitive. Muscimol mimicked GABA, whereas baclofen was inactive. The releasing effects produced by concns. of GABA >10 .mu.M were largely prevented by SKF 89976A, SKF 100330A, and SKF100561, 3 novel GABA uptake inhibitors. When present together, GABA

uptake blocker and bicuculline counteracted entirely the GABA effects. The release of [3H]5-hydroxytryptamine in synaptosomes from various central nervous system (CNS) regions was not affected by GABA. Apparently, GABA can enhance [3H]NA release not only through GABA-A receptors but also by penetrating into NA terminals through a GABA uptake system. This implies coexistence of carriers for NA and GABA uptake on the same nerve terminal. The carrier coexistence occurs in selective central nervous system areas. The phenomenon appears to be transmitter-selective.

L28 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2002 ACS
AN 1987:208292 CAPLUS
DN 106:208292
TI Regional selectivity of a .gamma.-aminobutyric acid-induced [3H]acetylcholine release sensitive to inhibitors of .gamma.-aminobutyric acid uptake
AU Bonanno, Giambattista; Raiteri, Maurizio
CS Ist. Farmacol. Farmacogn., Univ. Genova, Genoa, 16148, Italy
SO J. Neurochem. (1987), 48(5), 1454-8
CODEN: JONRA9; ISSN: 0022-3042
DT Journal
LA English
AB The effects of GABA [56-12-2] on the release of 3H-labeled acetylcholine (ACh) [51-84-3] were studied in synaptosomes prepd. from rat hippocampus, cerebral cortex, hypothalamus, and striatum and prelabeled with [3H]choline. When synaptosomes were exposed in superfusion to exogenous GABA (0.01-0.3 mM) the basal release of newly synthesized [3H]ACh was increased in a concn.-dependent way in hippocampus, cortex, and hypothalamus nerve endings. In contrast, the release of [3H]ACh was not affected by GABA in striatal synaptosomes. The effect of GABA was not antagonized by bicuculline or picrotoxin. Muscimol caused only a slight insignificant increase of [3H]ACh release when tested at 0.3 mM whereas, at this concn., (-)-baclofen was totally inactive. The GABA-induced release of [3H]ACh was counteracted by SKF 89976A [85375-85-5], SKF 100561 [**89203-55-4**], and SKF 100330A [85375-88-8], 3 selective GABA uptake inhibitors. In selective areas of the rat brain, GABA causes the release of [3H]ACh following penetration into cholinergic nerve terminals through a GABA transport system.

L28 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2002 ACS
AN 1985:442656 CAPLUS
DN 103:42656
TI N-Substituted pyrrolidineacetic acids and their esters
IN Bondinell, William E.; Lafferty, John J.; Zirkle, Charles L.
PA Smithkline Beckman Corp., USA
SO U.S., 7 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4514414	A	19850430	US 1982-436232	19821025

OS CASREACT 103:42656
GI



I



II



III

AB Pharmaceutical compns. useful as inhibitors of GABA [56-12-2] uptake comprise the title compds. I [R = cyclohexyl, thienyl, or (un)substituted Ph; R1 and R2 = H, Cl, F, Me, or MeO; R3 = H or Me; R4 = H or C1-3 alkyl; n = 2 or 3], II (R1, R2, R3, and R4 an n as above), and III (R1 and R4 as above) and their optical isomers. I were prepd. by the reaction of an alkenyl halide with an ester of an N-substituted pyrrolidineacetic acid (IV), II were prepd. by the reaction of IV with a diphenylalkyl group, and III were prepd. by the reaction of IV with an ester of an appropriately substituted phenylalkyne. Thus, a capsule formulation contained 1-(4,4-diphenyl-3-butenyl)-3-pyrrolidineacetic acid (I; R = Ph, R1-R4 = H) [**89203-55-4**] 50, Mg stearate 2, and lactose 200 mg/capsule.

L28 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2002 ACS
AN 1985:160041 CAPLUS
DN 102:160041
TI Orally active and potent inhibitors of .gamma.-aminobutyric acid uptake
AU Ali, Fadia E.; Bondinell, William E.; Dandridge, Penelope A.; Frazee, James S.; Garvey, Eleanor; Girard, Gerald R.; Kaiser, Carl; Ku, Thomas W.; Lafferty, John J.; et al.
CS Dep. Med. Chem., Smith Kline French Lab., Philadelphia, PA, 19101, USA
SO J. Med. Chem. (1985), 28(5), 653-60
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
GI



I

AB GABA [56-12-2]-uptake inhibitors that are more potent, more lipophilic, and in limited testing, at least as selective as the parent amino acids were obtained by alkylation of the appropriate butyric-, cyclohexane- and piperidinecarboxylic and pyrrolinidineacetic acids. The ability of these

alkylated amino acids to inhibit Na-dependent, high-affinity GABA uptake was measured after preincubation for 15 min with rat brain synaptosomes. N-(4,4-Diphenyl-3-butenyl)-3-piperidinecarboxylic acid (I) [85375-85-5] is a specific GABA-uptake inhibitor more potent, more lipophilic and, as selective as the nonalkylated parent; I and its analogs also exhibited anticovulsant activity in rodents. Structure-activity relations are discussed.

AN 1991:42580 CAPLUS
DN 114:42580
TI Preparation of N-(4-heterocyclyl-3-buten-1-yl)guvacines, -nipecotic acids, and -.beta.-homoprolines as central nervous system agents
IN Sonnewald, Ursula
PA Novo Industri A/S, Den.
SO U.S., 14 pp. Cont.-in-part of U.S. Ser. No. 755, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4931450	A	19900605	US 1988-259235	19881017
PRAI	DK 1986-51		19860107		
	DK 1986-956		19860303		
	US 1987-755		19870106		

OS MARPAT 114:42580
AB R1R2C:CHCH2CH2R3 [I; R1 = (un)substituted Ph; R2 = furanyl, thienyl, pyridyl, or pyrrolyl ortho-substituted with C1-7 alkyl or halo; R3 = 3-carboxypiperidin-1-yl, 3-carboxy-1,2,5,6-tetrahydropyridin-1-yl, or 3-(carboxymethyl)pyrrolidin-1-yl] which exhibit .gamma.-aminobutyric acid-uptake inhibitory activity, i.e. selective enhancement of **GABA** activity on the central nervous system, and may be useful for treatment of, e.g. pain, anxiety, and epilepsy, and as sedatives and hypnotics, are prepd. Thus, 1-chloro- and iodo-4-(N-methylpyrrol-2-yl)-4-phenylbut-3-ene were stirred with Et (R)-nipecotate in Me2CO contg. K2CO3 for 12 days at room temp. to give, after sapon. and acidification with aq. HCl, I.HCl [R1 = Ph, R2 = N-methylpyrrol-2-yl, R3 = (R)-3-carboxypiperidin-1-yl] (II). II free base showed an antiepileptic activity with the ratio of ED50 in a rotarod test/ED50 in a sinus tone-induced convulsion test of 28. Tablets and capsules contg. II free base were prepd.
IT **130397-51-2P 130397-54-5P 130397-57-8P**
130397-60-3P 130397-63-6P 130397-67-0P
130397-69-2P 130397-72-7P 130397-75-0P
130397-78-3P 130397-81-8P 130397-84-1P
130397-87-4P 130397-90-9P 130397-93-2P
130397-96-5P 130397-99-8P 130398-02-6P
130398-05-9P 130398-07-1P 130398-10-6P
130398-13-9P 130398-16-2P 130398-19-5P
130398-22-0P 130398-24-2P 130398-26-4P
130398-29-7P 130398-32-2P 130398-35-5P
130398-38-8P 130398-41-3P 130398-44-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as central nervous system agent)
RN 130397-51-2 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(1-methyl-1H-pyrrol-2-yl)-4-phenyl-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-54-5 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(2-methylphenyl)-4-(1-methyl-1H-pyrrol-2-yl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-57-8 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(3-methyl-2-thienyl)-4-phenyl-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-60-3 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(1-ethyl-1H-pyrrol-2-yl)-4-(2-methylphenyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-63-6 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(2-methylphenyl)-4-(1-propyl-1H-pyrrol-2-yl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-67-0 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(2-methylphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-69-2 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(2-ethylphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-72-7 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(2-ethylphenyl)-4-(3-ethyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)

RN 535-75-1 REGISTRY
CN 2-Piperidinecarboxylic acid (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Pipecolic acid (8CI)
OTHER NAMES:
CN (.+-.)-2-Piperidinecarboxylic acid
CN (.+-.)-Pipecolic acid
CN (.+-.)-Pipecolinic acid
CN (RS)-2-Piperidinecarboxylic acid
CN .alpha.-Pipecolinic acid
CN 2-Carboxypiperidine
CN Dihydrobaikiane
CN DL-2-Piperidinecarboxylic acid
CN DL-Pipecolic acid
CN DL-Pipecolinic acid
CN Hexahydro-2-picolinic acid
CN **Homoproline**
CN Pipecolinic acid
CN Piperolinic acid
FS 3D CONCORD
DR 4043-87-2
MF C6 H11 N O2
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, DDFU, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MRCK*, NAPRALERT, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

673 REFERENCES IN FILE CA (1962 TO DATE)
50 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
674 REFERENCES IN FILE CAPLUS (1962 TO DATE)
11 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

AN 1991:42580 CAPLUS
DN 114:42580
TI Preparation of N-(4-heterocyclyl-3-buten-1-yl)guvacines, -nipecotic acids, and -.beta.-homoprolines as central nervous system agents
IN Sonnewald, Ursula
PA Novo Industri A/S, Den.
SO U.S., 14 pp. Cont.-in-part of U.S. Ser. No. 755, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4931450	A	19900605	US 1988-259235	19881017
PRAI	DK 1986-51		19860107		
	DK 1986-956		19860303		
	US 1987-755		19870106		

OS MARPAT 114:42580
AB R1R2C:CHCH2CH2R3 [I; R1 = (un)substituted Ph; R2 = furanyl, thienyl, pyridyl, or pyrrolyl ortho-substituted with C1-7 alkyl or halo; R3 = 3-carboxypiperidin-1-yl, 3-carboxy-1,2,5,6-tetrahydropyridin-1-yl, or 3-(carboxymethyl)pyrrolidin-1-yl] which exhibit .gamma.-aminobutyric acid-uptake inhibitory activity, i.e. selective enhancement of **GABA** activity on the central nervous system, and may be useful for treatment of, e.g. pain, anxiety, and epilepsy, and as sedatives and hypnotics, are prepd. Thus, 1-chloro- and iodo-4-(N-methylpyrrol-2-yl)-4-phenylbut-3-ene were stirred with Et (R)-nipecotate in Me2CO contg. K2CO3 for 12 days at room temp. to give, after sapon. and acidification with aq. HCl, I.HCl [R1 = Ph, R2 = N-methylpyrrol-2-yl, R3 = (R)-3-carboxypiperidin-1-yl] (II). II free base showed an antiepileptic activity with the ratio of ED50 in a rotarod test/ED50 in a sinus tone-induced convulsion test of 28. Tablets and capsules contg. II free base were prepd.
IT **130397-51-2P 130397-54-5P 130397-57-8P**
130397-60-3P 130397-63-6P 130397-67-0P
130397-69-2P 130397-72-7P 130397-75-0P
130397-78-3P 130397-81-8P 130397-84-1P
130397-87-4P 130397-90-9P 130397-93-2P
130397-96-5P 130397-99-8P 130398-02-6P
130398-05-9P 130398-07-1P 130398-10-6P
130398-13-9P 130398-16-2P 130398-19-5P
130398-22-0P 130398-24-2P 130398-26-4P
130398-29-7P 130398-32-2P 130398-35-5P
130398-38-8P 130398-41-3P 130398-44-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as central nervous system agent)
RN 130397-51-2 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(1-methyl-1H-pyrrol-2-yl)-4-phenyl-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-54-5 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(2-methylphenyl)-4-(1-methyl-1H-pyrrol-2-yl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-57-8 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(3-methyl-2-thienyl)-4-phenyl-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-60-3 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(1-ethyl-1H-pyrrol-2-yl)-4-(2-methylphenyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-63-6 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(2-methylphenyl)-4-(1-propyl-1H-pyrrol-2-yl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-67-0 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(2-methylphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-69-2 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(2-ethylphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-72-7 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(2-ethylphenyl)-4-(3-ethyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-75-0 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(1-ethyl-1H-pyrrol-2-yl)-4-phenyl-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-78-3 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(4-fluorophenyl)-4-(1-methyl-1H-pyrrol-2-yl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-81-8 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(3-methyl-2-furanyl)-4-(2-methylphenyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-84-1 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-(2,4-dimethylphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-87-4 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(4-chloro-2-methylphenyl)-4-(1-methyl-1H-pyrrol-2-yl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-90-9 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(4-chloro-2-methylphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-93-2 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(2-fluorophenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-96-5 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(2,3-dimethoxyphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130397-99-8 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(4-chlorophenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130398-02-6 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(3-chlorophenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130398-05-9 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(2,5-dimethoxyphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130398-07-1 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(3,5-dichlorophenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130398-10-6 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(3,4-dichlorophenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130398-13-9 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(2,4-dichlorophenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130398-16-2 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(2-methoxyphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130398-19-5 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(3-methoxyphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130398-22-0 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(3,5-dimethoxyphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130398-24-2 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(2,6-dimethylphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130398-26-4 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(4-fluoro-2-methylphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130398-29-7 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(3-chloro-2-methylphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130398-32-2 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(3,4-dimethoxyphenyl)-4-(3-methyl-2-thienyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130398-35-5 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(3-chloro-2-thienyl)-4-(2-methylphenyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130398-38-8 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(3-bromo-2-thienyl)-4-(2-methylphenyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130398-41-3 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(3-chloro-2-thienyl)-4-phenyl-3-butenyl]- (9CI) (CA INDEX NAME)



RN 130398-44-6 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4-(3-bromo-2-thienyl)-4-phenyl-3-butenyl]-(9CI) (CA INDEX NAME)



RN 498-95-3 REGISTRY
CN 3-Piperidinecarboxylic acid (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Nipecotic acid (6CI, 7CI, 8CI)**
OTHER NAMES:
CN (.+-.)-.beta.-Homoproline
CN (.+-.)-Nipecotic acid
CN 3-Carboxypiperidine
CN DL-Nipecotic acid
CN Hexahydronicotinic acid
FS 3D CONCORD
DR 60252-41-7
MF C6 H11 N O2
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, DDFU, DRUGU, EMBASE, HODOC*, IPA, MEDLINE, MRCK*, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

316 REFERENCES IN FILE CA (1962 TO DATE)
18 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
316 REFERENCES IN FILE CAPLUS (1962 TO DATE)
6 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s guvacine/cn
L2 1 GUVACINE/CN

=> d

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
RN 498-96-4 REGISTRY
CN 3-Pyridinecarboxylic acid, 1,2,5,6-tetrahydro- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Nicotinic acid, 1,2,5,6-tetrahydro- (8CI)
OTHER NAMES:
CN 1,2,5,6-Tetrahydronicotinic acid
CN **Guvacine**
FS 3D CONCORD
MF C6 H9 N O2
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CHEMCATS, CSCHEM, DDFU, DRUGU, EMBASE, HODOC*, MEDLINE, MRCK*, NAPRALERT, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

76 REFERENCES IN FILE CA (1962 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
76 REFERENCES IN FILE CAPLUS (1962 TO DATE)



I



II



III

AB Pharmaceutical compns. useful as inhibitors of GABA [56-12-2] uptake comprise the title compds. I [R = cyclohexyl, thienyl, or (un)substituted Ph; R1 and R2 = H, Cl, F, Me, or MeO; R3 = H or Me; R4 = H or C1-3 alkyl; n = 2 or 3], II, (R1, R2, R3, and R4 an n as above), and III (R1 and R4 as above) and their optical isomers. I were prepd. by the reaction of an alkenyl halide with an ester of an N-substituted pyrrolidineacetic acid (IV), II were prepd. by the reaction of IV with a diphenylalkyl group, and III were prepd. by the reaction of IV with an ester of an appropriately substituted phenylalkyne. Thus, a capsule formulation contained 1-(4,4-diphenyl-3-butenyl)-3-pyrrolidineacetic acid (I; R = Ph, R1-R4 = H) **[89203-55-4]** 50, Mg stearate 2, and lactose 200 mg/capsule.

L28 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2002 ACS
AN 1985:160041 CAPLUS
DN 102:160041
TI Orally active and potent inhibitors of .gamma.-aminobutyric acid uptake
AU Ali, Fadia E.; Bondinell, William E.; Dandridge, Penelope A.; Frazee, James S.; Garvey, Eleanor; Girard, Gerald R.; Kaiser, Carl; Ku, Thomas W.; Lafferty, John J.; et al.
CS Dep. Med. Chem., Smith Kline French Lab., Philadelphia, PA, 19101, USA
SO J. Med. Chem. (1985), 28(5), 653-60
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
GI



I

AB GABA [56-12-2]-uptake inhibitors that are more potent, more lipophilic, and in limited testing, at least as selective as the parent amino acids were obtained by alkylation of the appropriate butyric-, cyclohexane- and piperidinecarboxylic and pyrrolinidineacetic acids. The ability of these

alkylated amino acids to inhibit Na-dependent, high-affinity GABA uptake was measured after preincubation for 15 min with rat brain synaptosomes. N-(4,4-Diphenyl-3-butenyl)-3-piperidinecarboxylic acid (I) [85375-85-5] is a specific GABA-uptake inhibitor more potent, more lipophilic and, as selective as the nonalkylated parent; I and its analogs also exhibited anticovulsant activity in rodents. Structure-activity relations are discussed.




```
ENTER (DIS), GRA, NOD, BON OR ?:end
L1   STRUCTURE CREATED

=> s l1
SAMPLE SEARCH INITIATED 13:00:55 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  27460 TO ITERATE

  3.6% PROCESSED    1000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       539324 TO   559076
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> screen 1840
L3    SCREEN CREATED

=> s l1 and l3
SAMPLE SEARCH INITIATED 13:01:09 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  18773 TO ITERATE

  5.3% PROCESSED    1000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       367277 TO   383643
PROJECTED ANSWERS:               0 TO        0

L4            0 SEA SSS SAM L1 AND L3

=> s l1 and l3 ful
FULL SEARCH INITIATED 13:01:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 376379 TO ITERATE

100.0% PROCESSED  376379 ITERATIONS                              0 ANSWERS
SEARCH TIME: 00.00.36

L5            0 SEA SSS FUL L1 AND L3
```




```
VPA 15-2/1/5 U
ENTER (DIS), GRA, NOD, BON OR ?:end
L10  STRUCTURE CREATED

=> s l10
SAMPLE SEARCH INITIATED 13:04:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  27460 TO ITERATE

  3.6% PROCESSED    1000 ITERATIONS                                  0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       539324 TO   559076
PROJECTED ANSWERS:               0 TO        0

L11           0 SEA SSS SAM L10

=> s l10 and l3
SAMPLE SEARCH INITIATED 13:04:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  18773 TO ITERATE

  5.3% PROCESSED    1000 ITERATIONS                                  0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       367277 TO   383643
PROJECTED ANSWERS:               0 TO        0

L12           0 SEA SSS SAM L10 AND L3

=> s l10 and l3 ful
FULL SEARCH INITIATED 13:05:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 376379 TO ITERATE

 69.9% PROCESSED  263210 ITERATIONS                                0 ANSWERS

100.0% PROCESSED  376379 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.37

L13           0 SEA SSS FUL L10 AND L3
```

L17 HAS NO ANSWERS
L17 STR



VAR G1=O/S
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 1
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

=> s l17 ful
FULL SEARCH INITIATED 13:08:50 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 314381 TO ITERATE

92.1% PROCESSED 289554 ITERATIONS 0 ANSWERS

100.0% PROCESSED 314381 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.23

L20 0 SEA SSS FUL L17

=> d l17
L17 HAS NO ANSWERS
L17 STR



REP G1=(0-5) CH2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 1
NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE

=> s l17 ful
FULL SEARCH INITIATED 12:06:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 225006 TO ITERATE

93.7% PROCESSED 210817 ITERATIONS 24 ANSWERS

100.0% PROCESSED 225006 ITERATIONS 24 ANSWERS
SEARCH TIME: 00.00.47

L19 24 SEA SSS FUL L17

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	144.84	145.05

FILE 'CAPLUS' ENTERED AT 12:07:01 ON 25 JUL 2002

FILE COVERS 1907 - 25 Jul 2002 VOL 137 ISS 4

FILE LAST UPDATED: 24 Jul 2002 (20020724/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s l19
L20 5 L19

=> d bib abs 1-5

L20 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2002 ACS
AN 2001:132748 CAPLUS
DN 134:178816
TI Preparation of amino acid derivatives as pharmaceuticals for treatment of neurological and neuropsychiatric disorders
IN Ognyanov, Vassil Iliya; Borden, Laurence A.; Bell, Stanley Charles; Zhang, Jing
PA Allelix Neuroscience Inc., USA
SO U.S., 52 pp., Cont.-in-part of U. S. Ser. No.656,063, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6191165	B1	20010220	US 1997-866007	19970530
	US 2001012857	A1	20010809	US 2001-757011	20010109
PRAI	US 1996-41503P	P	19960531		
	US 1996-41504P	P	19960531		
	US 1996-655912	B2	19960531		
	US 1996-656063	B2	19960531		
	US 1997-44387P	P	19970227		
	US 1997-70900P	P	19970227		
	US 1997-808754	B2	19970227		
	US 1997-808755	A2	19970227		
	US 1997-807682	A2	19970228		
	US 1997-866007	A3	19970530		

OS MARPAT 134:178816
AB Amino acid derivs. R2RxRyXR1NR3(R3*)nCR4R4*R5 [X = N, C (R2 not present when X = N); R2 = H, alkyl, alkoxy, cyano, alkanoyl, etc.; Rx, Ry = aryl, heteroaryl, adamantyl, or nonarom. ring linked to X via a single bond, alkylene, etc.; R1 = alkylene, iminooxyethylene, etc.; R3 = H, alkyl, (un)substituted Ph or phenylalkyl, etc.; R3* = alkyl, O; n = 0, 1; R4, R4* = H, alkyl, hydroxyalkyl; R5 = (un)substituted carbamoyl, carboxy, aminosulfonyl, phosphoryl, etc.] were prepd. as pharmaceuticals for treatment of neurol. and neuropsychiatric disorders. Thus, N-(4,4-diphenyl-3-butenyl)glycine Et ester was by alkylation of glycine Et ester hydrochloride with 4-bromo-1,1-diphenyl-1-butene. Binding assays to measure interaction of compds. with the glycine site on the NMDA receptor are illustrated.
RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2002 ACS
AN 2000:157915 CAPLUS
DN 132:194656
TI Preparation of proline derivatives and related compounds as GABA uptake inhibitors

IN Wanner, Klaus; Fuelep, Guenther; Hoefner, Georg
PA Germany
SO Ger. Offen., 36 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19840611	A1	20000309	DE 1998-19840611	19980905
	WO 2000014064	A2	20000316	WO 1999-EP6486	19990903
	WO 2000014064	A3	20000720		
	W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RU, TR, US, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9959726	A1	20000327	AU 1999-59726	19990903
	EP 1109783	A2	20010627	EP 1999-968664	19990903
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	DE 1998-19840611	A	19980905		
	WO 1999-EP6486	W	19990903		

OS MARPAT 132:194656
GI



I

AB Title compds. [I; R1-R7 = H, OH, halo, cyano, alkyl, alkenyl, alkynyl, (substituted) aryl, heteroaryl, etc.; R1R2 and/or R3R4 and/or R5R6 = (substituted) alkylidene, O; pairs of adjoining R1-R7 = double bond; X = CO2M, group physiol. convertible to CO2M; M = H, pharmaceutically acceptable cation; Z = Y3CO, Y2C:CR15, Y2C:NO; R15 = H, alkyl, halo; Y = (substituted) aryl, heteroaryl; A1 = (CR8R9)n, (substituted) alkylene, or a combination thereof; n .gtoreq.2; R8, R9 = H, alkyl, halo, OH, etc.; A2 = (CR10R11)m; R10, R11 = H, alkyl, halo; m .gtoreq.2], were prepd. as GABA uptake inhibitors (no data). Thus, L-proline Me ester hydrochloride (prepn. given), KI, K2CO3, and 4,4-diphenylbut-3-en-1-yl bromide were stirred 46 h in acetone to give 52.4% Me (S)-N-(4,4-diphenylbut-3-en-1-yl)pyrrolidine-2-carboxylate.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2002 ACS
AN 1998:668212 CAPLUS
DN 130:24646
TI Asymmetric allylations of chiral enamines via 1,3-diphenyl-.pi.-allylnickel complexes
AU Hiroi, Kunio; Endo, Taichi; Kato, Fumiko
CS Tohoku Coll. Pharm., Sendai, 981-8558, Japan
SO Annual Report of the Tohoku College of Pharmacy (1997), 44, 127-134
CODEN: TYKNAQ; ISSN: 0495-7342
PB Tohoku Yakka Daigaku
DT Journal
LA Japanese
OS CASREACT 130:24646

GI



I II III



IV V

AB Ni-catalyzed asym. allylation of 2-phenylpropanal or 2,2-diphenylacetaldehyde with 1,3-diphenylpropenyl acetate to 2-methyl-2,3,5-triphenyl-4-propenal derivs.(I and II) or 2-phenyl-2,3,5-triphenyl-4-propanal (III), resp., was carried out via chiral enamines (styrylproline derivs.) [(S)-IV; R = CH2OH, CO2CMe3, 1-pyrrolidinylcarbonyl, CH2PPh2; R1 = Me, Ph] derived from the aldehydes and (S)-proline derivs. (V; R = same as above). A plausible mechanism of the asym. induction is proposed on the basis of stereochem. of the chiral enamines employed and the corresponding Ni complexes formed. Thus, a soln. of 0.447 mmol 1,3-diphenylpropenyl acetate in THF was added to 0.037 mmol bis(1,5-cyclooctadiene)nickel (Ni(COD)2) and 0.074 mmol 1,4-bis(diphenylphosphino)butane (dppb) and stirred for 30 min at room temp., followed by adding a soln. of 0.373 mmol (S)-IV (R = CH2OH) in THF, and the resulting mixt. was stirred for 72 h at room temp., treated with 10% aq. HCl and benzene, and refluxed for 1 h to give a mixt. of I (42% ee) and II (34% ee) in 75% yield.

L20 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2002 ACS
AN 1997:803807 CAPLUS
DN 128:48490
TI Preparation of amino acid derivatives as pharmaceuticals for treatment of neurological and neuropsychiatric disorders
IN Ognyanov, Vassil Iliya; Borden, Laurence; Bell, Stanley Charles; Zhang, Jing
PA Trophix Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9745115	A1	19971204	WO 1997-US9450	19970529
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2254833	AA	19971204	CA 1997-2254833	19970529
AU 9731530	A1	19980105	AU 1997-31530	19970529

	AU 730789	B2	20010315		
	EP 1014966	A1	20000705	EP 1997-926871	19970529
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9709501	A	20001107	BR 1997-9501	19970529
	CN 1327383	A	20011219	CN 1997-196821	19970529
	JP 2002515037	T2	20020521	JP 1997-543034	19970529
	NO 9805711	A	19981207	NO 1998-5711	19981207
PRAI	US 1996-655912	A	19960531		
	US 1996-656063	A	19960531		
	US 1997-808754	A	19970227		
	US 1997-808755	A	19970227		
	US 1997-807682	A	19970227		
	WO 1997-US9450	W	19970529		

OS MARPAT 128:48490

AB Amino acid derivs. R2RxRyXR1NR3(R3*)nCR4R4*R5 [X = N, C (R2 not present when X = N); R2 = H, alkyl, alkoxy, cyano, alkanoyl, etc.; Rx, Ry = aryl, heteroaryl, adamantyl, or nonarom. ring linked to X via a single bond, alkylene, etc.; R1 = alkylene, iminooxyethylene, etc.; R3 = H, alkyl, (un)substituted Ph or phenylalkyl, etc.; R3* = alkyl, O; n = 0, 1; R4, R4* = H, alkyl, hydroxyalkyl; R5 = (un)substituted carbamoyl, carboxy, aminosulfonyl, phosphoryl, etc.] were prepd. as pharmaceuticals for treatment of neurol. and neuropsychiatric disorders. Thus, N-(4,4-diphenyl-3-butenyl)glycine Et ester was by alkylation of glycine Et ester hydrochloride with 4-bromo-1,1-diphenyl-1-butene. Binding assays to measure interaction of compds. with the glycine site on the NMDA receptor are illustrated.

L20 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2002 ACS

AN 1986:50792 CAPLUS

DN 104:50792

TI Anti-histamine compounds

IN Coker, Geoffrey George; Findlay, John William Addison

PA Wellcome Foundation Ltd., UK

SO Brit. UK Pat. Appl., 12 pp.
CODEN: BAXXDU

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2145081	A1	19850320	GB 1984-19264	19840727
	GB 2145081	B2	19860716		
	US 4610995	A	19860909	US 1984-635309	19840727
PRAI	GB 1983-20704		19830801		

GI



I

AB Amines I (R1 = H, alkyl; R2 = substituted alkyl; R1R2N = substituted N-contg. heterocycle; R3 = H, halo, OH, cyano, acyloxy, alkoxy, alkyl; R4

= R5 = H, R4R5 = bond; Z = N, CH) and their salts, useful as antihistaminics (data given), were prepd. Thus, treating L-proline Et ester with (2-phenoxyethyl)triphenylphosphonium bromide in EtOH gave [2-(2-ethoxycarbonylpyrrolidino)ethyl]triphenylphosphonium bromide, Wittig reaction of which with 2-(4-toluoyl)pyridine gave, after isomerization and sapon. with H2SO4, (E)-1-[3-(2-pyridyl)-3-14-tolylprop-2-enyl]pyrrolidine-2-carboxylic acid. Pharmaceutical formulations of I are presented.

AN 1997:724891 CAPLUS
DN 128:18717
TI GABAA, NMDA and AMPA receptors: a developmentally regulated 'menage a trois'
AU Ben-Ari, Yehezkel; Khazipov, Roustem; Leinekugel, Xavier; Caillard, Olivier; Gaiarsa, Jean-Luc
CS Hopital Port-Royal, Institut National Sante Recherche Medicale, Paris, 75014, Fr.
SO Trends in Neurosciences (**1997**), 20(11), 523-529
CODEN: TNSCDR; ISSN: 0166-2236
PB Elsevier
DT Journal; **General Review**
LA English
AB A review, with 101 refs., of the functional maturation of GABAergic and glutamatergic synaptic transmissions in the CNS. The main ionotropic receptors (GABAA, **NMDA** and AMPA) display a sequential participation in neuronal excitation in the neonatal hippocampus. **GABA**, the principal inhibitory transmitter in the adult CNS, acts as an excitatory transmitter in early postnatal stage. Glutamatergic synaptic transmission is first purely **NMDA**-receptor based and lacks functional AMPA receptors. Therefore, initially glutamatergic synapses are 'silent' at resting membrane potential, **NMDA** channels being blocked by Mg2+. However, when **GABA** and glutamatergic synapses are coactivated during the physiol. patterns of activity, GABAA receptors can facilitate the activation of **NMDA** receptors, playing the role conferred to AMPA receptors later on in development. Detg. the mechanisms underlying the development of this 'menage a trois' will shed light not only on the wide range of trophic roles of glutamate and **GABA** in the developing brain, but also on the significance of the transition from neonatal to adult forms of plasticity.

New search for structures by salts

9/9/03

US 4,514,419

Structures

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-[4-(3-chlorophenyl)-4-phenyl-3-butenyl]-, methyl ester, (E)- (9CI)
MF C23 H26 Cl N O2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):59

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Methanone, cyclohexylphenyl- (9CI)
MF C13 H16 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-[4-(3-chlorophenyl)-4-phenyl-3-butenyl]-, hydrochloride, (E)- (9CI)
MF C22 H24 Cl N O2 . Cl H

Double bond geometry as shown.



● HCl

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Cyclopropane, bromo- (6CI, 7CI, 8CI, 9CI)
MF C3 H5 Br
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-[4-(4-fluorophenyl)-4-phenyl-3-butenyl]-, methyl ester, (E)- (9CI)
MF C23 H26 F N O2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzene, 1,1'-(4-bromo-1-butenylidene)bis- (9CI)
MF C16 H15 Br

$Ph_2C{=}CH{-}CH_2{-}CH_2Br$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-[4-(4-fluorophenyl)-4-phenyl-3-butenyl]-, hydrochloride, (E)- (9CI)
MF C22 H24 F N O2 . Cl H

Double bond geometry as shown.



L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetonitrile, 1-(phenylmethyl)- (9CI)
MF C13 H16 N2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-[4,4-bis(4-fluorophenyl)-3-butenyl]-, methyl ester (9CI)
MF C23 H25 F2 N O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzene, 1-(4-bromo-1-phenyl-1-butenyl)-4-chloro-, (E)- (9CI)
MF C16 H14 Br Cl

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-(5,5-diphenyl-4-pentenyl)-, methyl ester (9CI)
MF C24 H29 N O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzene, 1-(4-bromo-1-phenyl-1-butenyl)-3-chloro-, (E)- (9CI)
MF C16 H14 Br Cl

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-(5,5-diphenylpentyl)-, methyl ester (9CI)
MF C24 H31 N O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzene, 1-(4-bromo-1-phenyl-1-butenyl)-4-fluoro-, (E)- (9CI)
MF C16 H14 Br F

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-(4-cyclohexyl-4-phenyl-3-butenyl)-, methyl ester, (E)- (9CI)

MF C23 H33 N O2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzenemethanol, .alpha.-(4-methoxybutyl)-.alpha.-phenyl- (9CI)
MF C18 H22 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-(4-cyclohexyl-4-phenyl-3-butenyl)-, hydrochloride, (E)- (9CI)
MF C22 H31 N O2 . Cl H

Double bond geometry as shown.



● HCl

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzene, (4-bromo-1-cyclohexyl-1-butenyl)-, (E)- (9CI)
MF C16 H21 Br

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-[4-phenyl-4-(2-thienyl)-3-butenyl]-, methyl ester, (E)- (9CI)
MF C21 H25 N O2 S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Thiophene, 2-(4-bromo-1-phenyl-1-butenyl)-, (E)- (9CI)
MF C14 H13 Br S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-[4-phenyl-4-(2-thienyl)-3-butenyl]-, (E)-, cyclohexylsulfamate (9CI)
MF C20 H23 N O2 S . C6 H13 N O3 S

CM 1

Double bond geometry as shown.



CM 2



L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-(4,4-diphenyl-3-butenyl)- (9CI)
MF C22 H25 N O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-(4-phenyl-3-butynyl)-, methyl ester (9CI)
MF C17 H21 N O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-(phenylmethyl)-, methyl ester, cyclohexylsulfamate (9CI)
MF C14 H19 N O2 . C6 H13 N O3 S

CM 1



CM 2



L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Butanoic acid, 4-amino- (9CI)
MF C4 H9 N O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-(4,4-diphenylbutyl)-, (2Z)-2-butenedioate (1:1) (9CI)
MF C22 H27 N O2 . C4 H4 O4

CM 1



CM 2

Double bond geometry as shown.



L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzene, 1-bromo-3-chloro- (6CI, 8CI, 9CI)
MF C6 H4 Br Cl
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-[4-(4-chlorophenyl)-4-phenyl-3-butenyl]-, methyl ester, (Z)- (9CI)
MF C23 H26 Cl N O2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Methanone, (4-chlorophenyl)phenyl- (9CI)
MF C13 H9 Cl O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-[4-(4-chlorophenyl)-4-phenyl-3-butenyl]-, hydrochloride, (Z)- (9CI)
MF C22 H24 Cl N O2 . Cl H

Double bond geometry as shown.



● HCl

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Methanone, (4-fluorophenyl)phenyl- (9CI)
MF C13 H9 F O
CI COM





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-[4-(3-chlorophenyl)-4-phenyl-3-butenyl]-, methyl ester, (Z)- (9CI)
MF C23 H26 Cl N O2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Methanone, (3-chlorophenyl)phenyl- (9CI)
MF C13 H9 Cl O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-[4-(3-chlorophenyl)-4-phenyl-3-butenyl]-, hydrochloride, (Z)- (9CI)
MF C22 H24 Cl N O2 . Cl H

Double bond geometry as shown.



● HCl

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Butane, 1-bromo-4-methoxy- (9CI)
MF C5 H11 Br O

Br— $(CH_2)_4$ — O — Me

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-[4-(4-fluorophenyl)-4-phenyl-3-butenyl]-, methyl ester, (Z)- (9CI)
MF C23 H26 F N O2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Butyn-1-ol, 4-phenyl- (7CI, 8CI, 9CI)

MF C10 H10 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-[4-(4-fluorophenyl)-4-phenyl-3-butenyl]-, hydrochloride, (Z)- (9CI)
MF C22 H24 F N O2 . Cl H

Double bond geometry as shown.



L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzene, 1,1'-(4-bromo-1-butenylidene)bis[4-fluoro- (9CI)
MF C16 H13 Br F2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-[4,4-bis(4-fluorophenyl)-3-butenyl]-, hydrochloride (9CI)
MF C22 H23 F2 N O2 . Cl H



L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzene, 1-(4-bromo-1-phenyl-1-butenyl)-4-chloro-, (Z)- (9CI)
MF C16 H14 Br Cl

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-(5,5-diphenyl-4-pentenyl)-, hydrochloride (9CI)
MF C23 H27 N O2 . Cl H



L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzene, 1-(4-bromo-1-phenyl-1-butenyl)-3-chloro-, (Z)- (9CI)
MF C16 H14 Br Cl

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-(5,5-diphenylpentyl)-, hydrochloride (9CI)
MF C23 H29 N O2 . Cl H



● HCl

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzene, 1-(4-bromo-1-phenyl-1-butenyl)-4-fluoro-, (Z)- (9CI)
MF C16 H14 Br F

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-(4-cyclohexyl-4-phenyl-3-butenyl)-, methyl ester, (Z)- (9CI)
MF C23 H33 N O2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzene, 1,1'-(5-bromo-1-pentenylidene)bis- (9CI)
MF C17 H17 Br

$Ph_2C{=}CH{-}(CH_2)_3{-}Br$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-(4-cyclohexyl-4-phenyl-3-butenyl)-, hydrochloride, (Z)- (9CI)
MF C22 H31 N O2 . Cl H

Double bond geometry as shown.



● HCl

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzene, (4-bromo-1-cyclohexyl-1-butenyl)-, (Z)- (9CI)
MF C16 H21 Br

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-[4-phenyl-4-(2-thienyl)-3-butenyl]-, methyl ester, (Z)- (9CI)
MF C21 H25 N O2 S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Thiophene, 2-(4-bromo-1-phenyl-1-butenyl)-, (Z)- (9CI)

MF C14 H13 Br S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-[4-phenyl-4-(2-thienyl)-3-butenyl]-, (Z)-, cyclohexylsulfamate (9CI)
MF C20 H23 N O2 S . C6 H13 N O3 S

CM 1

Double bond geometry as shown.



CM 2



L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI)
MF C23 H27 N O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-(4-phenyl-3-butynyl)- (9CI)
MF C16 H19 N O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, methyl ester, cyclohexylsulfamate (9CI)
MF C7 H13 N O2 . C6 H13 N O3 S

CM 1



CM 2



L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Benzonitrile (8CI, 9CI)
MF C7 H5 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-[4-(4-chlorophenyl)-4-phenyl-3-butenyl]-, methyl ester, (E)- (9CI)
MF C23 H26 Cl N O2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Methanone, diphenyl- (9CI)
MF C13 H10 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 3-Pyrrolidineacetic acid, 1-[4-(4-chlorophenyl)-4-phenyl-3-butenyl]-, hydrochloride, (E)- (9CI)
MF C22 H24 Cl N O2 . Cl H

Double bond geometry as shown.



L3 60 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Methanone, phenyl-2-thienyl- (9CI)
MF C11 H8 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT